MolOncology Profile Banner
Molecular Oncology Profile
Molecular Oncology

@MolOncology

Followers
2K
Following
2K
Media
1K
Statuses
2K

Open access journal highlighting new discoveries, technical developments and policies in basic, translational, and clinical cancer research. Part of FEBS Press.

Joined November 2017
Don't wanna be here? Send us removal request.
@MolOncology
Molecular Oncology
4 days
🎃 Our October issue is online👻 ❗ Read the EACR Viewpoint article by Gerlanda Vella and Maria Rescigno on the role of tumour-associated bacteria and their interplay with the tumour microenvironment in modulating cancer progression 🔓 https://t.co/YsSqvsgFUB #Neuroendocrine
0
0
0
@FEBS_JS
FEBS Junior Section
15 days
#Webinar - ''All eyes on me: advice to get your research further'' by Dr. Ioannis Tsagakis, Editor at @MolOncology and @FEBSOpenBio, FEBS Press ❓Couldn't join us live? #Video recording is available! 🔗Follow the link or scan the QR code: https://t.co/QUvdlsfN79
0
4
5
@XRBustelo
Xose R Bustelo
15 days
✅ And now, the award ceremony for the best 2️⃣ communications to the #2ndRASTherapySymposium of de ⁦@ciccancer⁩ of Salamanca. Thanks to ⁦@MolOncology⁩ for sponsoring them‼️ Congratulations to the awardees‼️@csic @usal@NIH⁩ ⁦@SmallGTPases
1
1
5
@MolOncology
Molecular Oncology
18 days
Patient-specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity ➡️ https://t.co/w8aE7cJ9E0 #Pharmacogenomics
0
0
1
@MolOncology
Molecular Oncology
21 days
📄 Did you know we publish EACR Viewpoints? 📣 Introduced in 2023 when Molecular Oncology became the affiliate journal of the EACR, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch. 🔓 You may access them here ➡️
0
0
1
@MolOncology
Molecular Oncology
22 days
📣 New month, new Commentary Not just a by-product: circular DNA molecules derived from V(D)J recombination are linked to worse prognosis in B-cell leukemia 🔓 https://t.co/rbgZfQuggJ 🖊️ @aventura71 #eccDNA #ecDNA
0
0
0
@MolOncology
Molecular Oncology
23 days
The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis ➡️ https://t.co/YV3EtgJAFG #CTCs #mCRC #Prognosis #Oncology #CRCSM
0
0
0
@MolOncology
Molecular Oncology
24 days
📖 Have you leafed through our September Issue? This Issue contains recent findings on how TME changes can alter cell function and treatment outcomes. It also highlights new therapeutic opportunities based on the TME’s dynamic landscape 🔓 https://t.co/an96Bl77CQ
0
0
1
@MolOncology
Molecular Oncology
25 days
Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia ➡️ https://t.co/m04nOf96vQ 🖊️ @HeckmanLab #AML #MCL1 #HemOnc
0
0
2
@MolOncology
Molecular Oncology
28 days
🤩 We are excited to be attending 🧠EACR Cancer Neuroscience🧠 next month 👥 Are you going? 👉 https://t.co/Wr9USq1tau #CancerResearch #BrainTumours #CNScancer #NeuroOncology
0
0
1
@MolOncology
Molecular Oncology
29 days
📣The joint publishing fellowship with the @EACRnews offers a remote placement at @MolOncology Get hands-on experience in scientific editing and visit the Heidelberg office ⏰Deadline Nov 7 ➡️ https://t.co/12yNRDyWqZ #PhDchat #PostDocChat #ECRchat #CancerResearch
0
0
0
@MolOncology
Molecular Oncology
30 days
Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism 🔦 https://t.co/NQVP5HlpEz #Glioma #Metabolism
0
0
0
@MolOncology
Molecular Oncology
1 month
📣 Don't miss our new Commentary Only the strong survive: therapeutic selective pressure drives medulloblastoma leptomeningeal metastasis 🖊️ @MSKCancerCenter @adrienne_boire #Leptomeningeal #Metastasis #Medulloblastoma
0
0
1
@MolOncology
Molecular Oncology
1 month
📢Call for papers 📭Submit your latest research in the field of #LiquidBiopsy ➡️Format: Research Article, Short Report or Method ➡️Details https://t.co/evcQA1NAM7 #ACTC2025 #CTC #ctDNA #Cancer
0
0
1
@MolOncology
Molecular Oncology
1 month
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy ➡️ https://t.co/vHvqnekm3O 🖊️ @GroupKyte #Microbiome #GutMicrobiota #BCSM #Immunotherapy
0
0
1
@MolOncology
Molecular Oncology
1 month
💻If you believe that curated data = quality controlled data then check out @datadryad 🤝Thanks to our partnership, authors can now enable the open sharing & reuse of their research data 👉 https://t.co/AEduhYskxW #OpenSource #OpenAccess #OpenResearch #OpenData #OpenScience
0
0
1
@MolOncology
Molecular Oncology
1 month
📄 Did you know we publish EACR Viewpoints? 📣 Introduced in 2023 when Molecular Oncology became the affiliate journal of the @EACRnews, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch. 🔓 You may access them here ➡️
0
0
0
@MolOncology
Molecular Oncology
1 month
Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics 🔦 https://t.co/XCwmNtsNXY #Fragmentomics #ctDNA #DNAmet #DNAmethylation
0
3
5
@MolOncology
Molecular Oncology
2 months
The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients 👉 https://t.co/dHvWpN0CqQ #ROS1 #NSCLC #Oncofusions
0
1
2
@MolOncology
Molecular Oncology
2 months
⚠️Did you know? 📣Molecular Oncology is an affiliate journal with Review Commons, meaning #ReviewedPreprints can be transferred directly to the journal for editorial consideration without restarting #PeerReview
0
0
1